HM | CT | p-value | |
Subjects n | 21 | 23 | |
Severe exacerbations# n per patient | 2.0 (1.0–4.0) | 3.0 (1.0–4.0) | 0.38 |
Duration of treatment with systemic corticosteroids days per patient | 10.0 (5.0–17.0) | 12.0 (4.0–22.0) | 0.88 |
Unscheduled visits n per patient | 5.0 (3.0–7.0) | 3.0 (2.0–7.0) | 0.30 |
Lung function | |||
Pre-β2-agonist | |||
FEV1 % pred | 95.4 (89.3–104.8) | 90.1 (74.6–97.3) | 0.13 |
FEF25–75% % pred | 63.6 (60.0–70.7) | 66.0 (47.2–77.7) | 0.76 |
Post-β2-agonist | |||
FEV1 % pred | 105.2 (98.8–97.3) | 96.2 (85.4–107.0) | 0.07 |
FEF25–75% % pred | 85.7 (68.4–97.7) | 77.1 (62.8–95.6) | 0.44 |
ICS dose μg equivalent BUD·day−1 | 1000 (800–1200) | 1200 (800–2000) | 0.86 |
Data are presented as median (interquartile range), unless otherwise stated. HM: home monitoring; CT: conventional treatment; FEV1: forced expiratory volume in 1 s; % pred: % predicted; FEF25–75%: forced expiratory flow at 25–75% of forced vital capacity; ICS: inhaled corticosteroids; BUD: budesonide. #: adjusted for age.